Cagri Sema
Cagri Sema supplies cagrilintide (CAS 1415456-99-3), a long-acting acylated amylin analogue, alongside semaglutide (CAS 910463-68-2), a GLP-1 receptor agonist peptide, the two-molecule combination studied in Phase 3 trials for appetite regulation and metabolic research. Synedica UK offers this kit for sale strictly for laboratory and in-vitro research use, not as a licensed medicine.
£190.00
Form: Injection Kit
Quantity
Form: Injection Kit
Storage & Handling
Storage (Lyophilized): Store at -20°C in a dry, desiccated environment. – After Reconstitution: Store reconstituted peptide at 2–8°C and use within 30 days. For long-term storage, aliquot and freeze at -20°C. Avoid repeated freeze-thaw cycles. – Reconstitution: Reconstitute in sterile bacteriostatic water or appropriate buffer depending on experimental needs.
â ï¸ This product is sold strictly for in vitro research and laboratory use only. It is not for human or veterinary use. By purchasing or using this product, the buyer agrees they have read, understood and accept the Terms & Conditions of Synedica UK. Terms & Conditions.
Cagrilintide and semaglutide combined — commonly referred to by the Novo Nordisk trial name CagriSema — is one of the most-discussed metabolic research combinations following its Phase 3 results, and demand for the research-grade blend has followed. Listings for it, however, often repeat a headline trial percentage without explaining what each molecule actually is or distinguishing trial results on the licensed drug from the research product itself. This page sets out what Cagri Sema is, what current clinical research has found, and how to verify what arrives before it goes anywhere near the bench.
What Cagrilintide and Semaglutide Are
Cagrilintide is a long-acting, acylated amylin analogue — a peptide designed to activate amylin receptors rather than the GLP-1 receptor pathway. Amylin receptor signalling is studied for its role in satiety signalling via the brainstem, distinct from the incretin pathway that semaglutide targets. Cagrilintide carries CAS number 1415456-99-3, molecular formula C194H312N54O59S2, and a molecular weight of approximately 4,409.0 g/mol.
Semaglutide is a 31-amino-acid GLP-1 receptor agonist peptide, structurally related to human glucagon-like peptide-1 but modified for extended half-life. It carries CAS number 910463-68-2, molecular formula C187H291N45O59, and a molecular weight of approximately 4,113.6 g/mol. Because cagrilintide and semaglutide act on two different receptor pathways — amylin and GLP-1 respectively — they are studied together as a dual-pathway combination rather than as two versions of the same mechanism.
What Current Research Says
The pivotal Phase 3 trial for this combination, REDEFINE 1, was published in the New England Journal of Medicine in 2025. Across 3,417 adults with obesity or overweight and at least one weight-related comorbidity (excluding type 2 diabetes), the 68-week, placebo- and active-controlled trial compared once-weekly cagrilintide 2.4 mg plus semaglutide 2.4 mg ("CagriSema") against cagrilintide alone, and placebo. With full treatment adherence, CagriSema produced a mean body-weight reduction of 22.7%, compared with 11.8% for cagrilintide alone and 2.3% for placebo. On an intent-to-treat basis, the combination produced a 20.4% mean reduction versus 3.0% for placebo. Secondary outcomes included 60.2% of CagriSema participants achieving at least 5% weight loss and 40.4% achieving at least 25% weight loss, with roughly half of participants with obesity reaching a BMI below 30 kg/m² by trial end (Garvey et al., 2025, N Engl J Med).
Semaglutide's own pivotal trial data and cagrilintide's monotherapy dose-finding data are documented separately on their individual research literature; the REDEFINE 1 result above describes the combined-molecule trial specifically. None of these findings constitute a treatment claim for this research-use product; they describe outcomes recorded in a registered clinical trial of the two molecules under medical supervision, not what a laboratory-use compound sold by Synedica UK does for an individual.
Specifications
| Property | Cagrilintide | Semaglutide |
|---|---|---|
| Receptor target | Amylin receptors (AMY) | GLP-1 receptor |
| CAS number | 1415456-99-3 | 910463-68-2 |
| Molecular formula | C194H312N54O59S2 | C187H291N45O59 |
| Molecular weight | ≈4,409.0 g/mol | ≈4,113.6 g/mol |
| UK legal / regulatory status | Not licensed as a medicine under the Human Medicines Regulations 2012 as sold here — supplied strictly for laboratory research | |
Both sets of figures are independently verifiable against public chemical databases such as PubChem, and researchers are encouraged to cross-check batch-specific documentation against these reference values rather than relying on a listing description alone.
Purity, Batch Testing and Certificate of Analysis Standards
Every Cagri Sema kit offered for sale is supplied with third-party analytical documentation rather than a single purity percentage repeated across listings. A Certificate of Analysis (COA) should show the specific batch or lot number, the analytical method used (typically HPLC or mass spectrometry), the measured purity result for that batch, and the issuing laboratory. Given the high commercial demand for this combination since its Phase 3 results were published, researchers should treat COA-on-request-only listings and vague sourcing claims as a red flag rather than an oversight. See our contact page to request a Certificate of Analysis for a specific batch.
Sourcing and Verification
Buying a high-demand combination like cagrilintide and semaglutide from a UK-based supplier does not remove the need to verify what arrives. Before ordering, check that the listing states research-use status clearly, that batch documentation is offered rather than promised only "on request," and that each compound's identity (CAS number, molecular formula) is independently verifiable against a source such as PubChem. Cagri Sema is offered for sale on this basis, with documentation available per batch. Researchers examining related metabolic peptides may also find the Synedica Semaglutide GLP-1 Pen Kit and Synedica Retatrutide 40mg Injection Kit relevant, and the full catalogue is browsable on the research products page.
Frequently Asked Questions
What is Cagri Sema used for?
It supplies cagrilintide and semaglutide together for laboratory and in-vitro research into amylin-receptor and GLP-1-receptor signalling and appetite-regulation pathways. It is not sold for any therapeutic, dietary, or performance use.
What is the difference between cagrilintide and semaglutide?
They target different receptor pathways. Cagrilintide is a long-acting amylin analogue acting on amylin receptors, while semaglutide is a GLP-1 receptor agonist. They are structurally distinct peptides studied together because their combined receptor activity has been examined in dual-pathway metabolic research.
Is it legal to buy cagrilintide and semaglutide as research chemicals in the UK?
UK researchers and laboratories can lawfully purchase compounds such as cagrilintide and semaglutide when they are supplied and marketed strictly for research or in-vitro use rather than as a medicine. This product is not licensed under the Human Medicines Regulations 2012 (SI 2012/1916) and has not been assessed by the MHRA for human safety or efficacy under that route, so it must not be purchased for human or veterinary use.
What does the Certificate of Analysis (COA) show?
A COA should confirm the batch number, the analytical testing method (typically HPLC or mass spectrometry), the measured purity for that specific batch, and the issuing laboratory, allowing a researcher to verify what a given batch actually contains rather than relying on a generic listing description.
How is the CAS number used to verify these compounds?
CAS 1415456-99-3 identifies cagrilintide and CAS 910463-68-2 identifies semaglutide. Researchers can cross-check these numbers, along with the molecular formulas (C194H312N54O59S2 for cagrilintide; C187H291N45O59 for semaglutide) and molecular weights, against an independent database such as PubChem to confirm chemical identity before use.
What has clinical research found about the cagrilintide-semaglutide combination?
The REDEFINE 1 Phase 3 trial, published in the New England Journal of Medicine in 2025, examined 3,417 adults with obesity or overweight over 68 weeks. With full treatment adherence, the combination produced a mean weight reduction of 22.7%, compared with 11.8% for cagrilintide alone and 2.3% for placebo. These findings describe a registered clinical trial of the molecules under medical supervision; they are not claims about this research-use product.
How does the combination compare with cagrilintide alone?
In the same REDEFINE 1 trial, cagrilintide alone produced a mean weight reduction of 11.8% versus 2.3% for placebo, roughly half the reduction seen with the combined cagrilintide-semaglutide treatment (22.7%), reflecting the trial's dual-pathway rationale.
Is cagrilintide a peptide?
Yes. Cagrilintide is a synthetic, acylated peptide analogue of human amylin, engineered for an extended half-life. It is structurally distinct from GLP-1 receptor agonist peptides such as semaglutide.
Does the product form (injection kit) affect the research application?
The kit format is a delivery/packaging format only. This listing makes no dosing, administration, or reconstitution recommendations; researchers determine their own protocols in line with their institution's research and safety governance.
How should Cagri Sema be stored before use?
Store according to the conditions printed on the batch documentation and product label, generally in cool, dry, dark conditions. Exact storage parameters and shelf life are batch-specific and confirmed on the accompanying documentation.
Can this product be used in human or veterinary applications?
No. It is sold strictly for laboratory and in-vitro research use. It is not a medicine, is not for human or veterinary use or consumption, is not licensed under the Human Medicines Regulations 2012, and has not been assessed by the MHRA for safety or efficacy under this listing.
Does Synedica UK ship Cagri Sema within the UK?
Yes, this product is offered for UK delivery to research buyers.
Where can I buy Cagri Sema for research use?
It is available for sale directly from Synedica UK, supplied with batch documentation and third-party testing for verified UK research buyers.
Related Reading
Author: Synedica UK Science & QA Team
Last updated: 29 August 2026